Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

A sensibly constructed option for short-term tax-exempt income. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.